JP2016500251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500251A5 JP2016500251A5 JP2015545522A JP2015545522A JP2016500251A5 JP 2016500251 A5 JP2016500251 A5 JP 2016500251A5 JP 2015545522 A JP2015545522 A JP 2015545522A JP 2015545522 A JP2015545522 A JP 2015545522A JP 2016500251 A5 JP2016500251 A5 JP 2016500251A5
- Authority
- JP
- Japan
- Prior art keywords
- target
- cancer
- subject
- infectious agent
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 5
- 239000012678 infectious agent Substances 0.000 claims 4
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732760P | 2012-12-03 | 2012-12-03 | |
| US61/732,760 | 2012-12-03 | ||
| US201361801187P | 2013-03-15 | 2013-03-15 | |
| US61/801,187 | 2013-03-15 | ||
| PCT/US2013/072918 WO2014089113A1 (en) | 2012-12-03 | 2013-12-03 | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002712A Division JP7132858B2 (ja) | 2012-12-03 | 2019-01-10 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016500251A JP2016500251A (ja) | 2016-01-12 |
| JP2016500251A5 true JP2016500251A5 (enExample) | 2017-01-19 |
Family
ID=49877017
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545522A Pending JP2016500251A (ja) | 2012-12-03 | 2013-12-03 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2019002712A Active JP7132858B2 (ja) | 2012-12-03 | 2019-01-10 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2021065226A Pending JP2021113197A (ja) | 2012-12-03 | 2021-04-07 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2023045137A Pending JP2023078356A (ja) | 2012-12-03 | 2023-03-22 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002712A Active JP7132858B2 (ja) | 2012-12-03 | 2019-01-10 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2021065226A Pending JP2021113197A (ja) | 2012-12-03 | 2021-04-07 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2023045137A Pending JP2023078356A (ja) | 2012-12-03 | 2023-03-22 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20150322119A1 (enExample) |
| EP (2) | EP2925350B1 (enExample) |
| JP (4) | JP2016500251A (enExample) |
| CN (2) | CN116637183A (enExample) |
| CY (1) | CY1121557T1 (enExample) |
| DK (1) | DK2925350T3 (enExample) |
| ES (1) | ES2715673T3 (enExample) |
| HR (1) | HRP20190574T1 (enExample) |
| HU (1) | HUE043903T2 (enExample) |
| LT (1) | LT2925350T (enExample) |
| PL (1) | PL2925350T3 (enExample) |
| PT (1) | PT2925350T (enExample) |
| RS (1) | RS58528B1 (enExample) |
| SI (1) | SI2925350T1 (enExample) |
| SM (1) | SMT201900242T1 (enExample) |
| WO (1) | WO2014089113A1 (enExample) |
Families Citing this family (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2277532A1 (en) | 2002-09-11 | 2011-01-26 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| TWI638833B (zh) | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| EP2925350B1 (en) | 2012-12-03 | 2019-01-30 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| TWI888366B (zh) | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2015153514A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| KR102568808B1 (ko) | 2014-04-07 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 면역활성화 항원 결합 분자 |
| SG11201609370QA (en) * | 2014-05-13 | 2016-12-29 | Chugai Pharmaceutical Co Ltd | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| DK3148579T3 (da) | 2014-05-28 | 2021-03-08 | Agenus Inc | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf |
| AU2015271709B2 (en) | 2014-06-06 | 2020-11-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| PE20170140A1 (es) * | 2014-07-16 | 2017-03-30 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer |
| CR20170060A (es) | 2014-08-19 | 2017-04-18 | Merck Sharp & Dohme | Anticuerpos anti tigit |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| KR20170072343A (ko) * | 2014-11-06 | 2017-06-26 | 제넨테크, 인크. | Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법 |
| MY187045A (en) * | 2014-12-23 | 2021-08-27 | Bristol Myers Squibb Co | Antibodies to tigit |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| KR20170109582A (ko) * | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| US10196445B1 (en) | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| EA035412B1 (ru) | 2015-05-29 | 2020-06-10 | Бристол-Майерс Сквибб Компани | Антитела к ox40 и их применение |
| JP6812364B2 (ja) | 2015-06-03 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌診断用抗ｇｉｔｒ抗体 |
| HK1251474A1 (zh) * | 2015-06-08 | 2019-02-01 | 豪夫迈‧罗氏有限公司 | 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法 |
| KR20180011839A (ko) * | 2015-06-08 | 2018-02-02 | 제넨테크, 인크. | 항-ox40 항체를 이용한 암의 치료 방법 |
| MX2017015811A (es) | 2015-06-12 | 2018-04-10 | Squibb Bristol Myers Co | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| EP3744340A3 (en) | 2015-07-16 | 2021-03-03 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
| CN108650886B (zh) | 2015-07-23 | 2022-07-05 | 英伊布里克斯公司 | 多价和多特异性gitr-结合融合蛋白 |
| EP3331917A1 (en) * | 2015-08-04 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| JP6976241B2 (ja) | 2015-08-14 | 2021-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗ｔｉｇｉｔ抗体 |
| PH12022553648A1 (en) | 2015-09-25 | 2024-03-11 | Genentech Inc | Anti-tigit antibodies and methods of use |
| UA125062C2 (uk) | 2015-10-01 | 2022-01-05 | Потенза Терапеутікс, Інк. | Анти-tigit антигензв'язуючі білки і способи їх застосування |
| BR112018002570A2 (pt) | 2015-10-02 | 2018-10-16 | Hoffmann La Roche | molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo |
| WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| CA3005855A1 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| SI3389699T1 (sl) | 2015-12-15 | 2024-07-31 | OncoC4, Inc. | Himerna in humanizirana monoklonska protitelesa proti humanemu ctla4 in uporabe le - teh |
| CN116514976A (zh) | 2016-03-04 | 2023-08-01 | Jn生物科学有限责任公司 | 针对tigit的抗体 |
| JP2019512271A (ja) | 2016-03-21 | 2019-05-16 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用 |
| CN109153727A (zh) * | 2016-04-15 | 2019-01-04 | 酵活有限公司 | 靶向免疫治疗剂的多特异性抗原结合构建体 |
| MX2018012472A (es) * | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| MX389710B (es) | 2016-05-27 | 2025-03-20 | Agenus Inc | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos. |
| FR3051794A1 (fr) * | 2016-05-31 | 2017-12-01 | Lab Francais Du Fractionnement | Anticorps pour le traitement de cancers |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| BR112018076525A2 (pt) | 2016-06-20 | 2019-04-02 | F-Star Beta Limited | membros de ligação a lag-3 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
| CA3032897A1 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| KR102576042B1 (ko) | 2016-10-11 | 2023-09-07 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| BR112019008223A2 (pt) * | 2016-11-03 | 2019-07-16 | Bristol-Myers Squibb Company | anticorpos anti-ctla-4 ativáveis e usos dos mesmos |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| CA3044664C (en) | 2016-11-30 | 2022-11-22 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| RU2769513C2 (ru) * | 2017-01-05 | 2022-04-01 | Кахр Медикал Лтд. | Слитый белок pd1-4-1bbl и способы его применения |
| PL3565828T3 (pl) | 2017-01-05 | 2022-04-04 | Kahr Medical Ltd. | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania |
| EA201991720A1 (ru) | 2017-02-17 | 2020-01-20 | Бристол-Маерс Сквибб Компани | Антитела к альфа-синуклеину и их применения |
| MX2019009660A (es) * | 2017-02-28 | 2019-10-02 | Bristol Myers Squibb Co | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. |
| EP3595720A4 (en) | 2017-03-14 | 2021-05-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING VISTA AT ACIDIC PH VALUE |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| WO2018191438A1 (en) | 2017-04-11 | 2018-10-18 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019008375A1 (en) * | 2017-07-06 | 2019-01-10 | Ucl Business Plc | Method for identifying responders to cancer treatment |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| US11512129B2 (en) | 2017-09-29 | 2022-11-29 | Jiangsu Hengrui Medicine Co., Ltd. | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| TWI816729B (zh) * | 2017-12-30 | 2023-10-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| IT201800001315A1 (it) * | 2018-01-18 | 2019-07-18 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Nuovi agenti terapeutici antitumorali |
| AU2019214865B2 (en) * | 2018-02-02 | 2025-04-10 | OncoC4, Inc. | Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| EP3746122A4 (en) * | 2018-02-02 | 2021-11-24 | OncoC4, Inc. | SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODY SELECTION AND DESIGN PROCESSES FOR CANCER THERAPY |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| IL277863B2 (en) | 2018-04-11 | 2026-02-01 | Inhibrx Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| CA3104778A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| AU2019301206B2 (en) | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| PL3820569T3 (pl) | 2018-07-12 | 2025-07-14 | Invox Pharma Limited | Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137 |
| BR112021003156A2 (pt) | 2018-08-23 | 2021-05-11 | Seagen, Inc. | composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit. |
| JP2021534216A (ja) * | 2018-08-29 | 2021-12-09 | 中央研究院Academia Sinica | 癌治療のためのシクロホスファミド化合物を有するナチュラルキラー細胞の組み合わせ |
| WO2020076799A1 (en) | 2018-10-09 | 2020-04-16 | Bristol-Myers Squibb Company | Anti-mertk antibodies for treating cancer |
| CN114008071B (zh) | 2018-12-27 | 2025-01-21 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| MX2021010997A (es) | 2019-03-13 | 2021-10-01 | Merck Sharp & Dohme Llc | Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1. |
| MX2022003204A (es) * | 2019-09-19 | 2022-04-18 | Bristol Myers Squibb Co | Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido. |
| IL294085A (en) | 2019-12-19 | 2022-08-01 | Bristol Myers Squibb Co | Combinations of dgk inhibitors and checkpoint antagonists |
| KR20220154140A (ko) | 2020-03-13 | 2022-11-21 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Pvrig 결합 단백질 및 이의 의학적 용도 |
| BR112022020741A2 (pt) | 2020-04-17 | 2022-12-20 | Hutchison Medipharma Ltd | Anticorpo anti-ox40 e usos do mesmo |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| US11820824B2 (en) | 2020-06-02 | 2023-11-21 | Arcus Biosciences, Inc. | Antibodies to TIGIT |
| MX2022015948A (es) * | 2020-07-02 | 2023-04-05 | Gigagen Inc | Proteínas de unión anti-ctla-4 y métodos de uso de estas. |
| CN121668303A (zh) | 2020-10-11 | 2026-03-17 | 百奥泰生物制药股份有限公司 | 抗pd-1抗体在联合用药中的应用 |
| CN116390949A (zh) | 2020-11-06 | 2023-07-04 | 百时美施贵宝公司 | 作为单一疗法给药和施用非岩藻糖基化抗ctla-4抗体 |
| TW202313682A (zh) | 2021-05-18 | 2023-04-01 | 英商凱麥博有限公司 | 抗icos抗體之用途 |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| JP2024535768A (ja) | 2021-09-15 | 2024-10-02 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｐｖｒｉｇ／ｔｉｇｉｔ二重特異性抗体を含む医薬組成物 |
| CN117940453A (zh) | 2021-09-15 | 2024-04-26 | 江苏恒瑞医药股份有限公司 | 特异性结合pd-1的蛋白及其医药用途 |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| US20260042840A1 (en) | 2022-04-07 | 2026-02-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| WO2024031032A1 (en) | 2022-08-05 | 2024-02-08 | Bristol-Myers Squibb Company | Anti-ctla-4 antibodies for treatment of kras mutant cancers |
| JP2026510747A (ja) | 2023-03-15 | 2026-04-10 | シャンハイ マブジェン バイオテック リミテッド | Ｐｄ－１／ｐｖｒｉｇ／ｔｉｇｉｔ結合タンパク質を含む医薬組成物及びその医薬的使用 |
| JP2025525507A (ja) * | 2023-06-30 | 2025-08-05 | カイミ バイオメディシン （チョントゥ） カンパニー リミテッド | グリコシルによって修飾された融合タンパク質、核酸分子、発現ベクター、宿主細胞及びそれらの使用 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025184211A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| US20250361320A1 (en) | 2024-02-27 | 2025-11-27 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| US20260115307A1 (en) | 2024-10-31 | 2026-04-30 | Bristol-Myers Squibb Company | Anti-fucosyl-gm1 antibody drug conjugates |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US20060034844A1 (en) * | 1996-12-04 | 2006-02-16 | The Regents Of The University Of California | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| AU2873999A (en) | 1998-02-24 | 1999-09-06 | Sisters Of Providence In Oregon | Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| NZ536746A (en) | 2002-06-13 | 2007-02-23 | Crucell Holland Bv | An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7786279B2 (en) * | 2003-02-27 | 2010-08-31 | Yeda Research And Development Co. Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection |
| EP1706424B1 (en) | 2004-01-12 | 2009-07-22 | Applied Molecular Evolution, Inc. | Fc region variants |
| CN101160324B (zh) | 2005-02-18 | 2013-04-24 | 米德列斯公司 | 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体 |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| ES2417147T3 (es) * | 2005-10-21 | 2013-08-06 | Revo Biologics, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
| JP2009514977A (ja) | 2005-11-08 | 2009-04-09 | メダレックス インコーポレーティッド | 免疫刺激性治療用抗体による治療に付随した腸炎に対するＴＮＦ−α遮断剤処置法 |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| EP1976883B1 (en) | 2006-01-17 | 2012-10-03 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
| WO2007133822A1 (en) * | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| EP2703011A3 (en) * | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用 |
| KR101577843B1 (ko) | 2007-12-14 | 2015-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 ｏｘ４０ 수용체에 대한 결합 분자 |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| BRPI1008692B8 (pt) | 2009-02-17 | 2021-05-25 | Ucb Biopharma Sprl | anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| WO2012027328A2 (en) | 2010-08-23 | 2012-03-01 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| JP2014509850A (ja) | 2011-03-06 | 2014-04-24 | メルク セロノ ソシエテ アノニム | 低フコース細胞株およびその使用 |
| PL2686347T3 (pl) * | 2011-03-16 | 2018-10-31 | Argenx Bvba | Przeciwciała przeciwko CD70 |
| EP3682896A1 (en) * | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| HRP20180858T1 (hr) | 2011-07-11 | 2018-09-21 | Glenmark Pharmaceuticals S.A. | Protutijela koja se vežu na ox40 i njihove uporabe |
| KR101685262B1 (ko) | 2011-08-23 | 2016-12-21 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-ｏｘ４０ 항체 및 이의 사용 방법 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| US20150037346A1 (en) * | 2012-02-23 | 2015-02-05 | Sloan-Kettering Institute For Cancer Research | Prediction of Responsiveness to Treatment with Immunomodulatory Therapeutics and Method of Monitoring Abscopal Effects During Such Treatment |
| EP2925350B1 (en) | 2012-12-03 | 2019-01-30 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
-
2013
- 2013-12-03 EP EP13811698.3A patent/EP2925350B1/en active Active
- 2013-12-03 EP EP18209431.8A patent/EP3508215A3/en not_active Withdrawn
- 2013-12-03 SM SM20190242T patent/SMT201900242T1/it unknown
- 2013-12-03 SI SI201331367T patent/SI2925350T1/sl unknown
- 2013-12-03 DK DK13811698.3T patent/DK2925350T3/da active
- 2013-12-03 CN CN202310218856.5A patent/CN116637183A/zh active Pending
- 2013-12-03 ES ES13811698T patent/ES2715673T3/es active Active
- 2013-12-03 PL PL13811698T patent/PL2925350T3/pl unknown
- 2013-12-03 CN CN201380072031.1A patent/CN104968364A/zh active Pending
- 2013-12-03 PT PT13811698T patent/PT2925350T/pt unknown
- 2013-12-03 RS RS20190387A patent/RS58528B1/sr unknown
- 2013-12-03 WO PCT/US2013/072918 patent/WO2014089113A1/en not_active Ceased
- 2013-12-03 HU HUE13811698A patent/HUE043903T2/hu unknown
- 2013-12-03 US US14/648,941 patent/US20150322119A1/en not_active Abandoned
- 2013-12-03 JP JP2015545522A patent/JP2016500251A/ja active Pending
- 2013-12-03 LT LTEP13811698.3T patent/LT2925350T/lt unknown
- 2013-12-03 HR HRP20190574TT patent/HRP20190574T1/hr unknown
-
2018
- 2018-02-13 US US15/895,655 patent/US20180312553A1/en not_active Abandoned
-
2019
- 2019-01-10 JP JP2019002712A patent/JP7132858B2/ja active Active
- 2019-04-16 CY CY20191100422T patent/CY1121557T1/el unknown
-
2020
- 2020-01-08 US US16/737,745 patent/US20200207816A1/en not_active Abandoned
-
2021
- 2021-04-07 JP JP2021065226A patent/JP2021113197A/ja active Pending
-
2023
- 2023-02-27 US US18/174,892 patent/US20230287064A1/en not_active Abandoned
- 2023-03-22 JP JP2023045137A patent/JP2023078356A/ja active Pending
-
2025
- 2025-01-17 US US19/030,567 patent/US20250236650A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515474A5 (enExample) | ||
| EP3508215A3 (en) | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins | |
| NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
| FI1897548T4 (fi) | T-solujen säätely | |
| WO2017132562A8 (en) | Antigen binding proteins that bind pd-l1 | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| JP2018514550A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| NZ604003A (en) | Monoclonal antibodies against her2 | |
| EP3421488A3 (en) | Multispecific antigen-binding molecules and uses thereof | |
| JP2013538057A5 (enExample) | ||
| UA114108C2 (uk) | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2015511962A5 (enExample) | ||
| WO2014055897A3 (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| EA201291243A1 (ru) | Антитела против респираторно-синцитиального вируса (рсв) и способы их применения | |
| JP2013231054A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| UA105760C2 (uk) | Антитіло проти bst2 | |
| HK1208499A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
| WO2014012007A3 (en) | Rspo3 binding agents and uses thereof | |
| WO2016130539A3 (en) | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof | |
| JP2015508063A5 (enExample) |